Editorials

Estimating Disease Prevalence and Incidence Using Administrative Data: Some Assembly Required
M.M. Ward .................................................. 1241

Biomarkers of Joint Damage in Rheumatoid Arthritis: Where Are We in 2013?
G. Ferraccioli, S. Alivernini, E. Gremese ............... 1244

Expression of B Cell Activating Factor (BAFF) and BAFF-binding Receptors in Rheumatoid Arthritis
M.J. Leandro, G. Cambridge ................................. 1247

Spondyloarthritis and Diffuse Idiopathic Skeletal Hyperostosis: Two Different Diseases That Continue to Intersect
I. Olivieri, S. D’Angelo, C. Palazzi, A. Padula ............ 1251

Articles

ACR/EULAR Remission Criteria for RA Maintain Reliable Performance When Evaluated in 44 Joints
Y. Kaneko, H. Kondo, T. Takeuchi ......................... 1254

ACPA and RF Fluctuate in Early Inflammatory Arthritis and Do Not Predict Clinical Outcomes
L. Barra, V. Bykerk, J.E. Pope, et al, and the CATCH Investigators ............................. 1259

Should We Redefine Treatment Targets in RA? Low Disease Activity Is Sufficiently Strict for Patients Who Are ACPA-negative
Y.M.R. de Punder, J. Hendriks, A.A. den Broeder, E. Valls Pascual, P.L.C.M. van Riel, J. Fransen ................. 1268

RA Disease Activity and Disability Affect the Risk of Serious Infection Events in RADIUS 1
A. Weaver, O. Troum, M. Hooper, A.S. Koenig, S. Chaudhari, J. Feng, D. Wenkert .................................. 1275

Bilateral Evaluation of the Hand and Wrist in Untreated Early Inflammatory Arthritis: A Comparative Study of Ultrasonography and Magnetic Resonance Imaging

BAFF and TACI Gene Expression Are Increased in Patients with Untreated Very Early RA

Serum Pyridinoline Levels and Prediction of Severity of Joint Destruction in RA
A. Krabben, R. Knevel, T.W.J. Huizinga, G. Cavet, A.H.M. van der Helm-van Mil .................................. 1303

Prognostic Factors and Radiographic Outcomes of Nontuberculous Mycobacterial Lung Disease in RA

DcR3 Mutations in Patients with Juvenile-onset SLE Lead to Enhanced Lymphocyte Proliferation
C. Chokdeemeeboon, P. Ammarinthnukrowh, S. Tongkobpetch, et al .................................................. 1316

Cross-cultural Validation of a Disease-specific Patient-reported Outcome Measure for SLE in Canada
J. Bourré-Tessier, A.E. Clarke, R.A. Nikolaitis-Preuss, M. Kosinski, S. Bernatsky, J.A. Block, M. Jolly ..................... 1327

Observation Period Effects on Estimation of SLE Incidence and Prevalence in Quebec
R. Ng, S. Bernatsky, E. Rahme ............................... 1334

Use of the Patient-generated Index in SSc to Assess Patient-centered Outcomes
S. de Achaval, M.A. Kallen, M.D. Mayes, M.A. Lopez-Olivo, M.E. Suarez-Almazor ............................. 1344

Hand Bone Loss in Patients with PsA: Posthoc Analysis of IMPACT II Data Comparing Infliximab and Placebo
M. Hoff, A. Kavana, G. Haugeberg .......................... 1347

Incremental Effects of Comorbidity on Quality of Life in Patients with PsA: J.A. Husted, A. Thavaneswaran, V. Chandran, D.D. Gladman ................................. 1353

Dactylitis in PsA: Prevalence and Response to Therapy in the Biologic Era
D.D. Gladman, O. Ziouzina, A. Thavaneswaran, V. Chandran .............................................................. 1357

Signal Hyperintensities on Brain MRI in Patients with Primary Sjögren Syndrome and Frequent Episodic Tension-type Headache: Relation to Platelet Serotonin Level and Disease Activity
H. Sarac, J. Markeljevic, V. Erdeljic, et al .................... 1360

Contents continued opposite inside back cover . . .